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Phthiocerol dimycocerosates and phenolic glycolipids (PGL) are considered
as major virulence elements of Mycobacterium tuberculosis, in particular
because of their involvement in cell wall impermeability and drug resistance.
The biosynthesis of these waxy lipids involves multiple enzymes, including
thioesterase A (TesA). We observed that purified recombinant M. tuberculo-
sis TesA is able to dimerize in the presence of palmitoyl-CoA and our 3D
structure model of TesA with this acyl-CoA suggests hydrophobic interaction
requirement for dimerization. Furthermore, we identified that methyl arachi-
donyl fluorophosphonate, which inhibits TesA by covalently modifying the
catalytic serine, also displays a synergistic antimicrobial activity with van-
comycin further warranting the development of TesA inhibitors as valuable
antituberculous drug candidates.
Keywords: methyl arachidonyl fluorophosphonate;Mycobacterium tuberculosis;
TesA; tetrahydrolipstatin; vancomycin
Mycobacterium tuberculosis is the causative agent of
tuberculosis (TB), a life-threatening disease represent-
ing a major global health burden. Globally, an esti-
mated 10.0 million people contracted TB in 2017 and
558 000 TB cases were resistant to rifampicin, one of
the first-line antituberculous drugs [1]. Among these
resistant strains, more than 80% were multidrug-resis-
tant (MDR), emphasizing the urgent need for finding
novel and effective drugs against MDR M. tuberculosis
strains [1].
Abbreviations
40-PP, 40-phosphopantetheine; AchE, acetylcholinesterase; DTNB, 5,50-dithiobis (2-nitrobenzoic) acid; FICI, fractional inhibitory concentration
index; HMG-CoA, 3-hydroxy-3-methylglutaryl-CoA; MAFP, methyl arachidonyl fluorophosphonate; MDR, multidrug-resistant; MIC, minimal
inhibitory concentration; MS, mass spectrometry; PDIM, phthiocerol dimycocerosates; PGL, phenolic glycolipids; SEC, size-exclusion chro-
matography; TB, tuberculosis; TE, thioesterase; TesA, thioesterase A; THL, tetrahydrolipstatin; WT, wild-type.
Many pathogenic slow-growing mycobacteria such
as M. tuberculosis, M. bovis and M. leprae, harbor an
unusual waxy cell envelope [2]. From the inside to the
outside, the mycobacterial cell wall consists in peptido-
glycan, covalently linked to arabinogalactan further
esterified by mycolic acids. Several complex extractible
lipids/glycolipids are embedded at the outer surface of
the envelope, further enhancing the impermeability [2].
Among these, the related phenolic glycolipids (PGL)
and phthiocerol dimycocerosates (PDIM), consisting
in either glycosylated phenolphthiocerols or phthio-
cerols esterified with two polyketide synthase-derived
multimethyl-branched mycocerosic acids, have been
reported to participate in virulence, drug resistance,
and host–pathogen interactions [3–9].
The gene cluster related to PDIM and PGL synthesis
is therefore considered as a ‘virulence gene cluster’ in
M. tuberculosis [10–12]. This cluster encodes various pro-
teins, including the phthiocerol or phenolphthiocerol
polyketide synthases (PpsA-E), the mycocerosic acid syn-
thase, fatty acid AMP ligases, the thioesterase A (TesA),
and proteins involved in lipid export [12–14]. The PpsA-
E processes the elongation of long-chain fatty acids
(C20–C22) by adding malonyl-CoA or methylmalonyl-
CoA extender units [2]. The release of the phthiocerol
and phenolphthiocerol chains from PpsE probably
requires TesA thioesterase (TE) activity as indicated by
the in vitro interaction of TesA with the C-terminal
region of PpsE [13] and the absence of PDIM and PGL
lipids in tesA deletion mutant ofMycobacterium marinum
[4,9]. The requirement of TesA in PDIM biosynthesis
was further confirmed in M. tuberculosis as mycobacte-
rial tesA disruption mutants were reported to be devoid
of PDIM [14,15]. Mycobacterial TesA may be therefore
considered as an interesting target to develop new antitu-
berculous drugs. M. tuberculosis TesA belongs to the
TE-II family [16] and its X-ray structure that fits the
structure fold of the a/b-hydrolase superfamily [17] has
revealed the presence of a lid subdomain covering its
active site [4,17]. Although, first characterization of
recombinant TesA enzymatic activities has also been pre-
viously reported [17], the exact mechanism behind TesA
requirement for PDIM biosynthesis was never demon-
strated. Indeed, the expected reaction of the membrane
bound [18] TesA hydrolyzing the thioester bond between
a phthiocerol (C33–C41) bound to the 40-phosphopan-
tetheine (40-PP) arms of acyl carrier protein (ACP)
domains of the PpsE protein – PpsE being also bound to
the transmembrane Mmpl7 transporter – was not yet
studied due to its complexity [19].
The recent crystal structure analysis of M. tuberculo-
sis TesA has confirmed Ser104-His236-Asp208 as the
catalytic triad [17].
Herein, we report a detailed characterization of the
TE activity of the recombinantM. tuberculosis TesA. In
the presence of the long-chain TE substrates, we demon-
strate that TesA undergoes a substrate dependent dimer-
ization. Furthermore, as found with the CyC analog
inhibitor, we showed that the methyl arachidonyl fluo-
rophosphonate (MAFP) can inhibit TesA activities by
forming a covalent bond with the catalytic serine resi-
due. We also observed that MAFP increased M. bovis
BCG susceptibility to vancomycin, and that such effect
is counteracted when TesA was overproduced by the
mycobacteria, therefore supporting the essential role of
TesA in PDIM biosynthesis and confirming the impact
of PDIM on vancomycin susceptibility.
Materials and methods
Chemicals
5, 50-dithiobis (2-nitrobenzoic) acid (DTNB, Ellman’s
Reagent), BSA essentially fatty acid free, malathion,
hexylphosphonic acid, and 4-nitrophenyl acetate were pur-
chased from Sigma Aldrich (St. Louis, MO, USA). Tetrahy-
drolipstatin (THL) was purchased from Cayman Chemical
(Ann Arbor, MI, USA). MAFP was from Sigma Aldrich. The
PageRulerTM Prestained Protein Ladder was from Thermo
Fisher Scientific (Waltham, MA, USA). All TE substrates
were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Substrates and inhibitor candidates are depicted in Fig. S1.
Fresh stock solutions of MAFP, THL, and hexylphosphonic
acid were prepared in DMSO (10 mM). Malathion stock solu-
tion (10 mM) was prepared in H2O. The 4-nitrophenyl acetate
stock solution (400 mM) was prepared in acetonitrile.
Cloning, expression, and purification
The DNA coding sequence corresponding to tesA was ampli-
fied by PCR from M. tuberculosis genomic DNA. The pri-
mers TesA-Fw 50-GGA ATC CAT ATG CTG GCC CGT
CAC GGA-30 and TesA-Rv 50-GGA ATC CTC GAG CTA
AGC TCG ATC ATG-30 were designed to introduce NdeI
and a XhoI restriction site at the 50 and 30 end of the coding
sequence, respectively. The amplified tesA coding sequence
was cloned into a modified pET-15b vector with a cleavage
site for the human rhinovirus 3C protease introduced
between NcoI and NdeI to replace the thrombin cleavage site
(Fw: 50-GAT ATA CCA TGG GTA CCA TGC ATC ATC
ATC-30 and Rv: 50-ATC GAT CAT ATG TGG GCC TTG
AAA AAG-30). Consequently, the cloned sequence allowed
for a N-terminal five histidine tag sequence followed by a
human rhinovirus 3C protease cleavage site before the
sequence of the target gene (tesA). The constructed plasmid
verified by sequencing was transferred into BL21(DE3)
Escherichia coli strain for protein production.
Briefly, for protein production, the BL21(DE3) E. coli
strain were grown at 37 °C in Luria-Bertani medium con-
taining 100 lgmL1 ampicillin. When the culture reached
an OD600 of 0.5, protein expression was induced overnight
at 18 °C by addition of 1 mM isopropyl b-D-1-thiogalac-
topyranoside.
The cells were collected and resuspended in a lysis buffer
(20 mM HEPES pH 8.0, 300 mM NaCl, 20 mM MgSO4,
10 mM imidazole, EDTA-free protease inhibitor cocktail,
and DNase 10 lgmL1), then lysed by three passages in
the EmulsiFlex-C3 (Avestin, Ottawa, Ontario, Canada) at
4 °C. The cell lysate was centrifuged for 30 min at
10 800 g at 4 °C (rotor SA-300 – Sorvall RC26 Plus) and
the supernatant was collected for purification on Ni–NTA
agarose column (Thermo Fisher Scientific) at 4 °C. The
protein was eluted in 20 mM HEPES, 300 mM NaCl, pH
8.0 containing 250 mM imidazole and further applied on a
PD-10 desalting column (GE Healthcare, Boston, MA,
USA) to remove the imidazole. The 59 His-tagged protein
was incubated overnight at 4 °C in the presence of the pro-
tease 3C (TesA/enzyme mass ratio of 75 : 1) for His-tag
removal. The protein was further purified by size-exclusion
chromatography (SEC) using Superdex 200 10/300 GL ana-
lytical column connected to an €AKTA purifier system (GE
Healthcare). The purity and integrity of the TesA protein,
concentrated using a Vivaspin 500 centrifugal concentrator
with a 5000 Da cutoff (Sartorius, Goettingen, Germany),
were analyzed by SDS/PAGE and mass spectrometry (MS),
respectively.
TesA thioesterase activity assay
Thioesterase activity was performed in 96-well plate for
spectrophotometric measures at 412 nm in order to detect
the reaction of the DTNB with thiol groups, yielding a col-
ored product as previously described [17,20]. Briefly, palmi-
toyl-CoA, decanoyl-CoA, 3-hydroxy-3-methylglutaryl CoA
(HMG-CoA), and malonyl-CoA were used as substrates.
The stock solutions (10 mM) of each substrate were freshly
prepared in 100 mM sodium phosphate (pH 7.2). The reac-
tion medium contained 100 mM sodium phosphate (pH 7.2),
2.5 mM DTNB, BSA and the enzyme in a final volume of
200 lL. The TE activity was followed by monitoring the
absorbance over time at 412 nm using spectrometer
(Tecan, M€annedorf, Switzerland). A e412 = 14 150 M
1cm1
was used to calculate the activity. BSA was added at a BSA/
acyl-CoA molar ratio of 1 : 4.5 [21]. The TE activity assay
was performed with 5 lM TesA and increasing concentra-
tions of substrates. TE activity is expressed in international
units (U), corresponding to 1 lmol of TNB2 released per
minute. Specific TE activity (SA) is expressed as mUmg1
of pure enzyme. First, we calculated the specific TE activity
in 1 mL (unitmL1): ((DA412 nm/minTest-DA412 nm/min-
Blank)/e412 9 Ve) 9 0.2 mL (=volume of reaction) 9 df
(=dilution factor); Ve being the volume (mL) of used enzyme.
Then we calculated the specific activity in unit per mg
enzyme knowing the concentration of mg enzyme per mL.
Curve fitting and evaluation of apparent Km and apparent
Vmax [22] were done using OriginPro 8.0 enzyme kinetics
program.
TesA esterase assay
The esterase activity assay was performed according to
Nguyen et al. [17]. The reactions were performed over a
period of 30 min. in a 96-well plate in 100 mM sodium
phosphate (pH 7.6) containing 2.5 lM TesA, 2 mM 4-nitro-
phenyl acetate and in the presence or absence of 0.5% (v/v)
Triton X-100. The absorbance was measured at 410 nm
(spectrophotometer; Tecan). To evaluate the effect of
MAFP on the TesA esterase activity, TesA and MAFP
were preincubated 30 min at 37 °C before the esterase
assay, as previously described with another inhibitor [17].
The residual activity in absence of inhibitor was considered
as 100%.
TesA thioesterase inhibitor screening
The reactions were performed without BSA in the presence
of 75 lM palmitoyl-CoA. Method A: Dose–response experi-
ments were performed in 200 lL by mixing all components
[TesA (5 lM), DTNB (2.5 mM), palmitoyl-CoA (75 lM),
and potential inhibitor] to measure TesA TE activity. The
absorbance was continuously read every 30 s at 412 nm for
60 min. Method B: Dose–response experiment was based
on the preincubation of TesA (in the presence or absence
of 0.5% v/v Triton X-100) and MAFP before measuring
the TesA TE activity. TesA (20 lM) was preincubated with
MAFP at different molar ratios for 5–20 min. The absor-
bance of the final mixture (200 lL) after the addition of
palmitoyl-CoA and DTNB was read at 412 nm for 60 min.
In each experiment, two controls were included. The first
control was performed with the same volume of solvent but
without inhibitor. The second control was performed
replacing TesA solution by the same volume of 50 mM
Tris-HCl, pH 7.5, 150 mM NaCl. DMSO final concentra-
tion was always less than 1.5% in each experiment.
TesA thermal stability assay
The SYPRO orange dye (Thermo Fisher Scientific) was
used to monitor protein unfolding. The thermal shift assay
was conducted in 96-well plate using the CFX96TM real-time
system (Bio-Rad, Hercules, CA, USA) under different con-
ditions (50–800 mM salt, pH, 5–20 lM MAFP). TesA
(5 lM) and diluted (2000 times dilution of the commercial
stock) SYPRO orange were present in all reactions in the
presence of 150 mM NaCl, 50 mM MES buffer (pH 5.5,
6.5), or Tris-HCl buffer (pH 7.5, 8.5). The samples were
heated from 20 to 80 °C with a heating rate of 1 °Cmin1.
The fluorescence intensity was recorded at Ex/Em = 465/
510 nm. The data were obtained from the Bio-Rad Preci-
sion Melt Analysis software 1.0 and exported as Microsoft
Excel spreadsheet. Plots of dF/dT (fluorescence intensity
difference, dF, in function of temperature difference, dT)
were obtained using the ORIGINPRO 8 software (OriginLab
Corporation, Northampton, MA, USA).
Mass spectrometry analysis of TesA-MAFP
interaction
Methyl arachidonyl fluorophosphonate was added to TesA
(20 lM) at a MAFP/protein molar ratio of 4 : 1 in 100 mM
sodium phosphate pH 7.2. The mixture was incubated at
37 °C for 1 h. To remove free MAFP, SEC (Superdex 200
10/300 GL) was performed in 50 mM Tris-HCl, 150 mM
NaCl, pH 7.5. PD MiniTrap TM G-25 (GE Healthcare) col-
umn was used to change the elution buffer to 10 mM
ammonium acetate (pH 6.9). Samples (~ 10 lg protein)
were lyophilized and dissolved in 5 lL of 50% acetonitrile/
1% formic acid (v/v). The intact mass of the MAFP/TesA
complex was analyzed by MS. The samples were loaded
into a nanoflow capillary (Thermo Fisher Scientific). ESI
mass spectra were acquired on a quadrupole time-of-flight
instrument (Q-Tof Ultima – Waters/Micromass) operating
in the positive ion mode, equipped with a Z-spray nano-
electrospray source. The spectra were recorded in the V
mode and represent the combination of 1 s scans. The
molecular mass of the protein was determined after pro-
cessing of the m/z spectra with the software MaxEnt 1
(Waters, Milford, MA, USA).
After the SEC, 10 lg MAFP-TesA complex and TesA
was kept for enzymatic digestion. The proteins were incu-
bated at 37 °C for 16 h in the presence of sequencing grade
trypsin/Lys-C (Promega, Madison, WI, USA) at an
enzyme/protein mass ratio of 1 : 25 in 50 mM Tris-HCl,
150 mM NaCl, pH 7.5. Peptides were dissolved in solvent A
[0.1% TFA in 2% ACN (v/v)], directly loaded onto
reversed-phase precolumn (Acclaim PepMap 100; Thermo
Scientific) and eluted in backflush mode. Peptide separation
was performed using a reversed-phase analytical column
(Acclaim PepMap RSLC, 0.075 9 250 mm; Thermo Scien-
tific) with a linear gradient of 4%-27.5% solvent B [0.1%
FA in 98% ACN (v/v)] for 100 min, 27.5–40% solvent B
for 10 min, 40–95% solvent B for 1 min, and holding at
95% for the last 10 min at a constant flow rate of
300 nLmin1 on an EASY-nLC 1000 UPLC system. The
resulting peptides were analyzed by Orbitrap Fusion Lumos
tribrid mass spectrometer (ThermoFisher Scientific). The
peptides were subjected to NSI source followed by tandem
mass spectrometry (MS/MS) in Fusion Lumos coupled
online to the UPLC. Intact peptides were detected in the
Orbitrap at a resolution of 120 000. Peptides were selected
for MS/MS using HCD setting as 30; ion fragments were
detected in the Orbitrap at a resolution of 30 000. A data-
dependent procedure alternating between one MS scan fol-
lowed by 20 MS/MS scans was applied for the top 20 pre-
cursor ions above a threshold ion count of 5.0 9 103 in the
MS survey scan with 20.0 s dynamic exclusion. The electro-
spray voltage applied was 2.1 kV. MS1 spectra were
obtained with an AGC target of 4E5 ions and a maximum
injection time of 50 ms, and MS [2] spectra were acquired
with an AGC target of 5E4 ions and a maximum injection
time of 100 ms. For MS scans, the m/z scan range was
350–1500. The resulting MS/MS data were processed using
Sequest HT search engine within Proteome Discoverer 2.2
against a homemade protein database containing the
recombinant TesA sequence. Trypsin/Lys-C was used as
cleavage enzyme allowing up to two missed cleavages, five
modifications per peptide, and up to seven charges. Mass
error was set to 10 p.p.m. for precursor ions and 0.2 Da
for fragment ions. False discovery rate was assessed using a
fixed value PSM validator, and thresholds for protein, pep-
tide, and modification site were specified at 1%. Site of
covalent modification with MAFP was manually validated.
TesA oligomeric state determination
TesA was analyzed by SEC using a Superdex 200 GL 10/
300 column. Fifty microlitre of purified TesA (5 lM in
50 mM phosphate buffer pH 6.8) was injected on the col-
umn pre-equilibrated in the same buffer. For TesA analysis
in the presence of thioester substrate, 15 mL of a palmi-
toyl-CoA solution (100 lM in 50 mM phosphate buffer pH
6.8) were injected on the column prior to TesA injection.
Aliquots of 0.5 mL were collected at the column output
and analyzed for protein content using the Bradford assay.
Data are represented as smoothed curves. Calculated
molecular weights were obtained based on the elution pro-
file of gel filtration standards (mixture of thyroglobulin,
gamma-globulin, ovalbumin, myoglobin, and vitamin B12
from Bio-Rad).
TesA overexpression in M. bovis BCG
Mycobacterium bovis BCG electrocompetent cells were pre-
pared according to previous reports [23,24]. For electropo-
ration, we used the MicroPulserTM Electroporator (Bio-
Rad) system. Briefly, 150 lL competent M. bovis BCG cells
was mixed with 1 lg of pVV16-tesA plasmid DNA [23] and
transferred to a 2 mm gap cuvette (VWR). After a signal
pulse of 3.0 kV, 5 mL Dubos medium (Becton, Dickinson
and Company) supplemented with 10% (v/v) albumin
(Sigma Aldrich) was immediately added to the suspension,
followed by incubation at 37 °C for 12 h with shaking.
Bacteria were then plated on the 7H11 mycobacteria agar
supplemented with 10% OADC containing kanamycin
(50 lgmL1) and hygromycin (100 lgmL1). After 2 week
incubation at 37 °C, colonies, corresponding to M. bovis
BCG-overTesA, were harvested for further experiments.
Drug susceptibility assay
Mycobacterium bovis BCG strains were grown in 25 cm2
flasks at 37 °C without shaking in Dubos medium (Becton,
Dickinson, Franklin Lakes, NJ, USA ) supplemented with
10% (v/v) albumin (Sigma Aldrich) to an OD600 of 0.3–0.9.
The macrodilution method was performed in 12 mL screw
tubes in 7H9 medium (Becton, Dickinson and Company)
containing 0.05% glycerol and 10% albumin–dextrose com-
plex. Five hundred microlitre inoculum diluted in the supple-
mented 7H9 medium to reach an optical density at 600 nm
(OD600) of 0.01 was added to 500 lL serial drug dilutions in
the same 7H9 medium. Tubes were place at 37 °C without
shaking. Growth or absence of growth was recorded on the
day that the growth of the 100-fold diluted drug-free inocu-
lum control became visible in order to assess the minimal
inhibitory concentration of the drugs (MIC, being the lowest
drug concentration inhibiting more than 99% of M. bovis
BCG strain bacterial growth) [25]. This experiment was
performed three times to check the reproducibility of the
MIC determination. The fractional inhibitory concentration
index (FICI) was calculated according to the checkerboard
method, as follows: FICI = FICa + FICb = MICab/MICa +
MICba/MICb. The MIC of the MAFP and vancomycin
alone (MICa and MICb, respectively), the MIC of the MAFP
in combination with a fixed vancomycin concentration
(MICab), and inversely the MIC of the vancomycin in
combination with a fixed MAFP concentration (MICba) were
obtained. The fixed concentrations were 4- and 20-fold lower
than the MICa or MICb, respectively. In agreement with the
checkerboard method, synergy is reached when the FICI is
< 0.5 [25].
Docking protocols
The X-ray structure of TesA determined in complex with
hexadecyl dihydrogen phosphate CyC17 (PDB: 6FVJ) was
used as the target structure to endeavor the docking studies
[17]. Chain A was selected for the docking calculations into
the monomeric structure of TesA and chains A and F were
selected for the dimeric structure. The X-ray water and
other ligand molecules were removed from the active site.
The TesA crystal structure was prepared with the Protein
Preparation Wizard workflow implemented in the Schr€odin-
ger package [26]. The initial 3D structures of the ligands
were generated using the Ligprep module (Schr€odinger,
LLC, New York, NY, USA, 2018). In the present work, the
binding region in the monomer was defined by a box cen-
tered on the phosphorus position of the 4-carbon long trun-
cated crystal CyC17 with a box length of 38 A. Docking was
performed using the Glide SP docking protocol and scoring
function which approximates a systematic search of posi-
tions, orientations, and conformations of the ligand in the
receptor binding site using a series of hierarchical filters
[27]. The default settings of Glide were used.
Results
Recombinant TesA expression and purification
The recombinant protein was overexpressed in a BL21
(DE3) E. coli strain and purified by immobilized metal
affinity chromatography. After cleavage of the His-tag,
TesA was further purified by size-exclusion chromato-
graphy (SEC, Fig. S2B-a). The purity of recombinant
TesA was determined by 12% SDS/PAGE and a single
band with an apparent molecular weight of ~ 27 kDa
was observed after Coomassie Brilliant Blue staining
(Fig. S2B-b). After His-tag cleavage, three additional
N-terminal residues (Gly-Pro-His) (Fig. S2A) remain
fused to TesA leading to a theoretical molecular mass
of 29 443 Da. The experimental molecular mass of
29 443 Da determined by MS totally agrees with this
theoretical value (Fig. S2B-c).
The recombinant TesA stability properties were
investigated by thermal shift assay. We examined the
impact of NaCl, pH, and MAFP on TesA thermal sta-
bility (Fig. S2C) and observed that increasing concen-
trations of NaCl and MAFP had a stabilizing effect
on the protein. The protein was also more stable
between pH 6.5 and 8.5.
Thioesterase activity of recombinant TesA
We first monitored TesA TE activity using palmitoyl-
CoA as thioester substrate at different temperatures
(4, 22, and 37 °C), and observed that the optimal tem-
perature was 37 °C (data not shown). The addition of
fatty acid-free BSA, that could reduce inhibition of TE
activity at high substrate concentrations, improved the
catalytic activity of TesA, as previously observed for
various thioesterases [21]. Control experiments were
performed in the absence of different component to
exclude nonspecific influence on reaction (data not
shown).
We tested TesA TE activity toward four different
CoA-derived substrates (Fig. S1A). Our results using
palmitoyl-CoA, HMG-CoA, and malonyl-CoA fitted
to the apparent Michaelis–Menten model (Fig. 1A,C,
D). The enzyme displayed a higher specific TE activity
(SA) for the long-alkyl chain and hydrophobic sub-
strates, palmitoyl-CoA (C16-SA = 34.8 mUmg1),
and decanoyl-CoA (C10-SA = 46.2 mUmg1). Malo-
nyl-CoA and HMG-CoA were not good substrates for
the TesA TE, as demonstrated by their specific activity
of 3.5 and 5.1 mUmg1, respectively. Moreover, the
apparent Vmax (
appVmax) (1.71  0.39) 9 108 Ms1)
of the reaction was about one-order of magnitude
faster (P value < 0.05) with a long-chain substrate
(C16) compared to HMG-CoA and malonyl-CoA
(Table 1). The affinity to substrate (appKm) of
HMG-CoA and malonyl-CoA were evaluated to be
42.4  7.7 lM and 27.6  11.3 lM, respectively.
The best turnover number (appkcat) was for palmitoyl-
CoA (3.42  0.78) 9 103s1. A sigmoidal curve was
observed with decanoyl-CoA, suggesting a potential
conformational change in the enzyme with this sub-
strate [28]. An oligomeric state of TesA endowed with
a homotropic activation mechanism may explain this
observation [29].
Since the TesA natural substrate featured a b-methyl
group in the phthiocerol derived thioesters (C31–C33)
bound to the mycobacterial PpsE protein [13], we also
evaluated TesA TE activity using the methylmalonyl-
CoA as substrate. TesA exhibited similar activity (P
value > 0.05) on methylmalonyl-CoA and malonyl-
CoA (SA = 3.6 mUmg1 and SA = 3.5 mUmg1,
respectively) (data not shown).
The addition of 0.5% Triton X-100, recently
reported to activate TesA esterase activity [17],
reduced TesA TE activity (P value < 0.05) using either
palmitoyl-CoA (Fig. S3) or malonyl-CoA (data not
shown) as substrate.
Oligomeric state of TesA
Size-exclusion chromatography was performed to eval-
uate the TesA oligomeric states (Fig. 2). Alone, the
enzyme behaves as a monomer. However, the addition
of palmitoyl-CoA into the SEC column with low
enzyme concentration, in order to reduce substrate
consumption during the assay, led to the protein elu-
tion at a lower retention volume with a native molecu-
lar weight close to 68 kDa, indicative of a dimeric
state.
Influence of potential inhibitors on TesA
activities
We first investigated the ability of four inhibitor candi-
dates to inhibit TesA TE activity. Hexylphosphonic
A B
C D
Fig. 1. Acyl-CoA thioesterase activity of
purified recombinant TesA in the presence
of different substrates: (A) palmitoyl-CoA,
(B) decanoyl-CoA, (C) HMG-CoA, and (D)
malonyl-CoA. The thioesterase activity
assay was performed with 5 lM TesA,
2.5 mM DTNB, BSA, and an increasing
concentration of substrate at 37 °C. BSA
was added at a BSA/acyl-CoA molar ratio
of 1 : 4.5. The data correspond to means
and standard deviations from at least three
independent experiments.
Table 1. Apparent (app) kinetic parameters of recombinant TesA with a series of different acyl-CoA as substrates.
Substrate
appVmax (Ms1) appKm(lM) appkcat (s1)
Value SD Value SD Value SD
Decanoyl-CoA NA NA – – NA NA
HMG-CoA 2.53 9 109* 1.49 9 1010 42.42 7.697 5.05 9 104 2.99 9 105
Palmitoyl-CoA 1.71 9 108 3.89 9 109 57.44 9.50 3.42 9 103 7.78 9 104
Malonyl-CoA 1.74 9 109 * 1.88 9 1010 27.64 11.33 3.49 9 104 3.76 9 105
The appVmax values with a symbol (*) are significantly different (P < 0.05) compared the value palmitoyl-CoA. NA, not applicable.
acid and malathion have been selected because of their
reactive organophosphate group. Malathion is known
to irreversibly inhibit the acetylcholinesterase (AchE)
after binding to the serine residue of AchE catalytic
site [31]. The THL (Orlistat) was chosen because it
was previously shown to interact with various a/b-hy-
drolases, including TesA [17,30], and the MAFP was
tested because it is a well-established irreversible inhi-
bitor for most serine enzymes, including some phos-
pholipases [32]. When the inhibition assay was
performed by using the method A – that is competitive
inhibition mixing altogether TesA (5 lM), the inhibi-
tor, the DTNB and the palmitoyl-CoA into the 96-well
plate – hexylphosphonic acid and malathion had no
influence on TesA TE activity. In contrast, MAFP
and, to a lesser extent, THL inhibited TesA TE activ-
ity (Fig. 3) in a concentration-dependent manner. With
MAFP, a maximal 52% inhibition was observed in all
tested experimental conditions, for example the com-
petitive assay (Method A) or by preincubating TesA
A B
Fig. 2. Gel filtration chromatography of TesA and TesA/palmitoyl-CoA complex. (A) TesA and TesA/palmitoyl-CoA complex, (B) Elution of
standard molecular mass marker proteins. Black diamonds: gel filtration standard; orange squares: TesA.
A B
C D
Fig. 3. Effect of different inhibitors on
TesA thioesterase activity. A–D. Method A
- The reaction medium (200 lL) contained
5 lM TesA, 75 lM palmitoyl-CoA, 2.5 mM
DTNB, with or without inhibitor. (A)
hexylphosphonic acid, (B) malathion, (C)
THL, and (D) MAFP, all components were
added together in the reaction medium.
Each plot is representative of three
independent experiments.
(Method B) with MAFP for 5 or 20 min before start-
ing the reaction with palmitoyl-CoA. In order to
potentially increase the access of MAFP to the TesA
catalytic site, we tested the impact of Triton X-100 in
the reaction. The presence of this surfactant during
preincubation of TesA with MAFP unexpectedly
reduced MAFP inhibitory activity (P < 0.05) in the
presence of palmitoyl-CoA (Fig. 4A). It is worth not-
ing that although at the used concentration, palmi-
toyl-CoA forms micelles [33] in solution; addition of
Triton X-100 has however been reported to have a
negative impact on such micelles formation [34]. Fur-
thermore, this nonionic detergent could also interfere
with the hydrophobic interactions between the
MAFP and TesA (see our docking analysis hereun-
der). This might explain the tendency of Triton X-
100 to decrease the MAFP induced inhibition
(Fig. 4A).
In parallel, we investigated the ability of MAFP
and THL to inhibit TesA esterase activity on the
small 4-nitrophenyl acetate substrate. Preincubation
with both MAFP and THL inhibited TesA esterase
activity in a concentration-dependent manner. The
MAFP inhibitor appeared to fully inactivate TesA
esterase activity while it only reduced by approxi-
mately 50% TesA TE activity using palmitoyl-CoA
as substrate (Fig. 4B).
Mass spectrometry analysis of TesA-MAFP
interaction
TesA incubated in the presence of MAFP at a protein/
inhibitor molar ratio of 1 : 4 was analyzed by MS. As
shown in Fig. 5, two main peaks at molecular masses
of 28 543 and 28 894 Da, and two minor ones at
29 442 and 29 793 Da were observed. The two minor
peaks correspond to the intact TesA (theoretical
molecular mass 29 443.1 Da), and to the TesA/MAFP
covalent adduct, respectively. The MS analysis shows
that a fraction of TesA is not bound by the MAFP
(Fig. 4A). The two main peaks also correspond to
TesA (28 543 Da) and to the MAFP-modified TesA
(28 894) but in both cases, the N terminus of TesA
was shortened by the loss of the GPHMLARH resi-
dues (Fig. S2A), as calculated from the protein
sequence (theoretical molecular masses: 28 543.1 and
28 893.6 Da, respectively). This N-terminal degrada-
tion could be due to TesA proteolysis by a protease
present in trace amounts in the TesA preparation that
could have digested TesA during the different steps of
Fig. 4. Residual activity of TesA. (A) Inhibition of thioesterase activity assay by MAFP. TesA was preincubated with various concentrations
of MAFP for 5 min. The reaction contained enzyme/inhibitor mixture, 10 mM DTNB, 75 lM palmitoyl-CoA, with or without 0.5% (v/v) Triton
X-100 in 100 mM sodium phosphonate buffer (pH 7.6). The data obtained in absence of Triton X-100 are significantly different (P < 0.05)
than those in the presence of Triton X-100. (B) Inhibition of esterase activity assay by MAFP or THL. TesA (2.5 lM) was preincubation with
various concentration of MAFP or THL for 30 min. The reaction contained enzyme/inhibitor mixture, 2 mM 4-nitrophenyl acetate, 0.5% (v/v)
Triton X-100 in 100 mM sodium phosphonate buffer (pH 7.6). The activity without inhibitor was considered as 100%. The data correspond to
means and standard deviations from at least three independent experiments.
Fig. 5. TesA-MAFP complex analysis by MS. Mass spectrum
showing the presence of TesA alone or modified by MAFP. ‘TesA -
GPHMLARH’ corresponds to the N-terminal degradation of the
protein resulting in the loss of the first eight residues.
the experiment. The mass shifts observed in the pres-
ence of MAFP are consistent with the covalent bind-
ing of the inhibitor on TesA with the loss of one
hydrogen and one fluorine atom (theoretical D
mass = 350.5 Da) [32]. After trypsin/Lys-C digestion
of the TesA/MAFP complex, the resulting peptides
were microsequenced by MS/MS. As expected, the
Ser104 was identified as the residue covalently modi-
fied by MAFP (Fig. S4).
Docking calculations
To rationalize the data showing that palmitoyl-CoA is
a better substrate than malonyl-CoA and that MAFP
only inhibits 50% of TesA TE activity in presence of
palmitoyl-CoA, we docked this substrate and inhibitor
in the 3D structure of TesA [17].
First, to validate our procedure, the noncovalent
docking of the propyl phosphate was performed and
compared with the crystal position of the 4-carbon
long truncated hexadecyl dihydrogen phosphate. The
phosphate group occupied the same position in the
docked poses and in the experimental crystal structure
therefore validating our docking procedure to evaluate
other compounds (Fig. S5).
The docked poses of palmitoyl-CoA in the binding site
of the monomeric TesA show one type of binding mode
which features the thioester group close to the active site
Ser104 and His236 (Fig. 6A,B). Docking calculations of
palmitoyl-CoA were also performed in the TesA dimer
with poses similar to those found for the monomer
(Fig. 6C), except for one top score pose, showing one
palmitoyl phosphate matching with the crystal phos-
phate. Remarkably, in the binding modes, the alkyl chain
of palmitoyl-CoA positions itself at the surface of the
monomer, facing the other monomer in the dimer
(Fig. 6B,D). This layout could contribute in promoting
the dimerization of the protein, as we observed by SEC.
In contrast to palmitoyl-CoA, the docked poses of
malonyl-CoA in the monomer present a variety of
A B
C
D
Fig. 6. Molecular docking in TesA monomer and dimer. (A and C): Close view of the binding pose of palmitoyl-CoA featuring its thioester
carbonyl group in the catalytic site of TesA monomer (A) and dimer (C); B: Molecular surface of TesA monomer bound to the palmitoyl-CoA
binding pose as shown in A; D: Molecular surface of palmitoyl-CoA bound in one catalytic site of TesA dimer as shown in C. Palmitoyl-CoA
is represented as ball-and-sticks and the catalytic residues (Ser104, Asp208 and His236) as sticks. In B and D, TesA is depicted as yellow
and purple cartoon.
binding modes in which either the carboxylate or one
of the phosphate groups or the thioester group fit a
position corresponding to the crystal phosphate
ligand group. These data might explain why the mal-
onyl-CoA is a poorer substrate than the palmitoyl-
CoA.
For MAFP, the best score docked poses show a
large variability in binding modes, including one posi-
tion with the fluorophosphonate group matching the
crystal ligand phosphate.
Finally, MAFP and palmitoyl-CoA were also
docked into one of the two binding sites of the dimer
featuring one palmitoyl-CoA molecule previously
bound by docking into the other active site (Fig. 6C).
Most of the MAFP poses occupy the second binding
site with the fluorophosphonate matching the crystal
ligand phosphate (Figs 7 and S6). As for palmitoyl-
CoA, no pose featuring the thioester group in the cat-
alytic pocket was generated. These findings provide a
possible explanation for the 50% TE activity inhibi-
tion by MAFP in presence of palmitoyl-CoA if one
assumes that palmitoyl-CoA features a better affinity
than MAFP for the first binding site which is
suggested by the docking scores (6.6 versus
3.9 kcalmol1).
MAFP increases vancomycin susceptibility
As PDIM deficient M. bovis BCG and M. tuberculosis
mutants are specifically more susceptible to van-
comycin [8,25], by a 100-fold factor, we assessed the
effect of MAFP on M. bovis BCG vancomycin suscep-
tibility. MAFP increased by more than 10-fold the sus-
ceptibility of M. bovis BCG to vancomycin (Table 2).
To investigate whether this growth inhibition resulted
from a synergy between MAFP and vancomycin, we
used the Checkerboard method to calculate the FICI.
The MIC of MAFP dropped from ≥ 10 to 1 lgmL1
in the presence of vancomycin (25 lgmL1), and the
MIC of vancomycin dropped from ≥ 500 to
25 lgmL1 in the presence of MAFP (1 lgmL1),
showing that this combination can inhibit M. bovis
BCG growth in synergy (FICI < 0.15) This synergy
would suggest that MAFP inhibited the PDIM biosyn-
thesis [8]. Since TesA could not be the only target, we
also considered the possibility that this MAFP effect
could be due to its interference with other proteins. To
solve this issue, we overexpressed TesA in M. bovis
BCG. Importantly, overexpression of TesA in
mycobacteria abrogated the observed synergy, strongly
suggesting that TesA inhibition by MAFP was
Table 2. Vancomycin susceptibility obtained in macrodilution series and analyzed by the checkerboard method for M. bovis BCG strains,
wild-type (WT) , or overexpression TesA (overTesA).
Strain
MIC (lgmL1)/FIC (lgmL1)/FICI
wtWT M. bovis BCG M. bovis BCG-overTesA
Treatment Vancomycin MAFP Vancomycin MAFP
Alone 500/–/– > 10/–/– 250/–/– > 10/–/–
+ 1 lgmL1 MAFP 25/0.05/< 0.15 –/–/– > 100/> 0.4/> 0.9 –/–/–
+ 25 lgmL1 –/–/– 1/< 0.1/< 0.15 –/–/– > 5/> 0.5/> 0.9
Fig. 7. Binding mode of MAFP bound in
one of the two catalytic sites of the TesA
dimer bound to palmitoyl-CoA in the other
site (pose shown on Fig. 6C,D). Molecular
surfaces of MAFP and palmitoyl-CoA are
colored in yellow and purple respectively.
Each TesA monomer is depicted as a
yellow and purple cartoon.
responsible for this synergistic growth inhibitory effect
with vancomycin (Table 2).
Discussion
Tuberculosis, caused by M. tuberculosis, is the ninth
leading cause of death worldwide and the leading
cause of death from a single infectious agent [1]. The
increase of MDR M. tuberculosis strain is alarming,
emphasizing the urgent need to find new antitubercular
drugs. The mycobacterial TesA protein was reported
to be required for PDIM biosynthesis, a lipid from the
outermost membrane of the mycobacterial cell wall,
necessary, among others, for mature biofilm formation
and drug resistance [4,6]. TesA is consequently consid-
ered as a potential target in anti-TB drug discovery
perspective. We therefore expressed and purified the
recombinant M. tuberculosis TesA to identify and ana-
lyze potential TesA inhibitors. We used acyl-CoA
derivatives as substrates as those are mimicking the
TesA natural substrate, a fatty acyl, elongated phthio-
cerol moiety joined by a thioester linkage to the phos-
phopantetheinyl arm of the ACP domain of the PpsE
during PDIM biosynthesis.
Unexpectedly, although the addition of detergent
(Triton X-100) increased TesA esterase activity, the
TesA TE activity was inhibited in the presence of
detergent. This was unexpected, as detergents have
been reported to increase TesA esterase activity by
promoting and stabilizing a lid opening process [17].
The difference of detergent effects on the TesA ester-
ase and TE activity could be due to the different
TesA/substrate interfaces, especially if we consider the
water insoluble pNP ester substrates used for the ester-
ase activity [17] and the water-soluble long-chain fatty
acyl-CoA thioester substrates used in this study. Our
hypothesis is that the hydrophobicity of the palmitoyl-
CoA acyl chain or its hydrolyzed product following
TesA activity could favor TesA dimerization (Fig. 6)
and consequently the TE activity. Conversely, in the
presence of detergents, this oligomerization could be
destabilized. Indeed, our docking model suggests that
the long-acyl chain of the palmitoyl-CoA could lie on
the external side of TesA (Fig. 6), just at the interface
of the crystallized dimer [17], an action that does not
occur with the small pNP ester substrates used in the
esterase assay. Interestingly, it has been previously
described that palmitoyl-CoA acts in fact just like a
detergent, by forming micelles when its concentration is
above its critical micelle concentration which is defini-
tively the case here [34]. Changes in the palmitoyl-CoA
micelle solutions composition, that is by the addition of
Triton X-100, have been previously described to inhibit
hydrolase activity; while the addition of serum albumin
was reported not only to prevent palmitoyl-CoA micelle
formation but also to activate the enzyme by interacting
with its hydrophobic regions [34,35]. The specific TE
activity on palmitoyl-CoA of our recombinant protein
(SA = 34.8 mUmg1) is relatively high in comparison
to the previously reported TE activity (6.82 mUmg1)
[17]. The BSA added, here, in our TE assay might have
promoted the fatty acid release in the catalytic site. In
contrast, the addition of Triton X-100 could have
increased the size of the palmitoyl-CoA micelle reducing
its accessibility to the catalytic site in the dimeric form,
by steric congestion.
Compared to the type III recombinant mycobacte-
rial FcoT TE activity [36], the recombinant TesA TE
activity showed a similar binding affinity (appKm value)
for palmitoyl-CoA but a 10-fold reduced turnover
number (appKm value). The use of a surrogate substrate
instead of the expected natural phthiocerol (C33–C41),
and the fact that this in vitro assay did not mimic
TesA in vivo steric environment – with a substrate
bound to the 40-PP arms of ACP domains of a huge
PKS protein, which is itself also bound to a transmem-
brane transporter – may explain such difference.
The sigmoidal TE reaction curve observed in the
presence of decanoyl-CoA further suggests that TesA
could act in an oligomeric state. This is not only in
agreement with its X-ray dimeric structure obtained
in the presence of covalently bound CyC17 inhibitor
[17] but also with our SEC analysis demonstrating
the dimeric state of TesA in the presence of palmi-
toyl-CoA. These results indicated that TesA under-
goes a substrate-induced dimerization. It is difficult
to know if TesA could dimerize in the bacteria when
interacting with its substrate, a C-33 phthiocerol
thioester precursor covalently attached to the phos-
phopantetheinyl arm of PpsE. However, considering
the hydrophobic chain of its native substrate and
the hydrophobic cavity of the ACP domain, it is
possible that such a TesA dimerization could take
place.
Some molecules have been reported either to bind
TesA, like THL, or to have chemical groups, like
phosphonate, with known inhibitory activity for possi-
ble interference with TesA catalytic activity [17,30].
The phosphate analog (CyC17) was reported to inhibit
TesA esterase activity by covalently binding to the cat-
alytic serine residue [17].
Here, we investigated the impact of four molecules
on TesA TE activity. The hexylphosphonic acid and
malathion did not affect the TesA TE activity
(Fig. 3A,B). As expected, we observed that THL is a
potent inhibitor of TesA TE activity (Fig. 3C), further
confirming that THL might be an interesting anti-TB
drug candidate [17,37]. Indeed, THL was shown to
reduce mycobacteria cell wall lipid biosynthesis, target-
ing various serine enzymes involved among others in
sulpholipids, mycolic acids, or PDIM biosynthesis
[25,37–39]. In addition, the effect of THL on the
mycobacterial cell wall integrity allowed to improve
susceptibility to other drugs, as observed with van-
comycin [25]. THL is mainly known as a pancreatic
lipase inhibitor, inhibiting the type-I fatty acid syn-
thase on its C-terminal thioesterase domain (TE). This
domain hydrolyzes the thioester bond between the
palmitate and the 40-PP moieties of an ACP [40–42].
This TE domain shares the canonical catalytic triad
(Ser-His-Asp) with other serine hydrolases [40], includ-
ing TesA [17]. Analysis of the crystal structure of the
TE domain–THL complex in human fatty acid syn-
thase shows that the palmitate-like inhibitor THL
binds to the hydrophobic pocket of TE domain [43].
THL is present in two states in the TE active site:
either covalently bound to the active-site serine or as a
hydrolyzed product. Its hexyl tail in these two different
states adopts different conformations, suggesting that
the hexyl tail conformation may play a critical role in
hydrolysis [41]. It was also reported that THL dis-
played inhibition on TesA using activity-based profil-
ing [30].
MAFP irreversibly binds and inhibits its targets
through phosphonylating active-site serine residues
[44]. In MAFP, the C20 alkyl chain on the fluorophos-
phonate might more easily target TesA catalytic site
than the less lipophilic organophosphorus malathion,
giving a possible explanation to their different TesA
inhibition abilities, despite common ability to attack a
nucleophilic serine catalytic residue. Furthermore,
MAFP has been reported to be a broad-spectrum Ser
active site inhibitor compared to malathion [45–47].
Indeed, the serine-reactive fluorophosphonate (FP) of
MAFP inhibited more M. tuberculosis esterases than
the E-600, THL, and PMSF inhibitors [48]. To better
characterize this inhibitor, we preincubated MAFP
and TesA at different molar ratios, before measuring
the reaction rate with palmitoyl-CoA (Fig. 4A). As
expected for a covalent inhibition, a dose-dependent
decrease in activity was observed but, surprisingly, the
inhibition did not proceed to full inactivation of the
enzyme. Around 50% residual activity was constantly
observed, even using high molar excess of MAFP
(16 : 1). Higher inhibitor concentration could not be
used due to low MAFP solubility. The addition of Tri-
ton X-100 (Fig. 4A) in the TE assay did not improve
the inhibition level. Longer reaction times (up to 1 h)
with a higher MAFP/TesA molar ratio, using a com-
petitive approach, putting all reagents together, or by
preincubating the enzyme with the MAFP, also failed
to induce more than 45% inhibition. However, MAFP
alone could completely inhibit TesA esterase activity
using p-nitrophenyl acetate as substrate (100% inhibi-
tion). This differential effect is thus dependent on the
substrate. Possible explanations could be that the posi-
tion of the palmitoyl hydrolyzed substrate still inter-
acting with TesA could inhibit MAFP/TesA
interaction (Figs 7 and S7). Indeed, both molecules
could interact with dimer interaction surface. How-
ever, this explanation would be satisfactory if the 50%
inhibition by MAFP on TesA TE activity was only
observed in a competitive experiment, which is not the
case. Therefore, there must be another explanation.
We believe that during the esterase assay, when using
pNP-acetate as substrate, TesA stays as a monomer
and pNP-acetate does not induce dimerization. Indeed,
according to our docking studies, long-acyl chain
could induce TesA dimerization via a hydrophobic
interaction which could not take place with the pNP-
acetate. When MAFP binds TesA, it could induce pro-
tein dimerization through its hydrophobic acyl chain,
as previously reported in the case of the phosphonate
inhibitor CyC17 [17]. Consequently, the second cat-
alytic site in the dimeric form could not be easily
reached by the MAFP. Indeed, we observed in MS
analysis that a fraction of TesA is not bound by the
MAFP. The MAFP-induced dimerization could in
turn inhibit the access of pNP-acetate to the second
catalytic site even in the presence of Triton X-100, as
the affinity of the long-acylated MAFP chain could
prevent further pNP-acetate/TesA interaction or acet-
ate release from TesA catalytic site by hydrolysis [49].
In the TE assay, the presence of palmitoyl-CoA
micelles may favor or only allow access to this sub-
strate inside the second MAFP induced, TesA dimeric
active-site entrance; thus resulting in 50% TE residual
activity Interestingly, we observed that MAFP can
slightly stabilizes the TesA protein in thermal shift
assay.
Therefore, the enzymatic outcomes using different
substrates, the dimerization induced by substrate
(palmitoyl-CoA), the 50% TE activity inhibition by
MAFP, the potential lid structure obtained from X-
ray crystal analysis [17], and our docking analyses are
all together suggesting that conformation changes
induced by substrate/inhibitor are interfering in TesA
function (Fig. S7). Indeed, our TesA-ligands models
(Figs 6 and 7) demonstrated that the TesA dimeriza-
tion induced by the palmitoyl-CoA also could affect
the MAFP binding.
Considering that MAFP is targeting more M. bovis
BCG enzymes than only TesA, the fact that MAFP
can synergize with vancomycin, like THL, and that
overexpression of TesA can abolish the MAFP syner-
gistic growth inhibition, further highlights that MAFP
effect to inhibit mycobacteria growth in synergy with
vancomycin can be attributed to TesA inactivation.
The fact that the synergy with vancomycin to inhibit
M. bovis BCG growth has been previously associated
with PDIM deficiency [8,25], and that TesA deficient
transposon M. tuberculosis mutants, were devoid of
PDIM, further suggest that MAFP could synergized
with vancomycin by impairing the PDIM synthesis
through TesA inhibition, as demonstrated in this
study, whereas TesA overexpression counteracted this
observed vancomycin susceptibility.
In conclusion, our study presents the biochemical
characterization of recombinant TesA TE/esterase
activity and the identification of a new inhibitor
MAFP, irreversibly binding to the TesA catalytic
Ser104 residue. We observed that MAFP increases the
susceptibility to vancomycin, potentially by inhibiting
TesA involved in PDIM biosynthesis. Although
MAFP is too toxic to be considered in the treatment
of human infection [31], our finding opens an addi-
tional new route for further development of anti-TB
drug candidates.
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